Antitumoral activity of rapamycin in renal angiomyolipoma associated with tuberous sclerosis complex - Wikidata - wikimedia - TriplyDB

Antitumoral activity of rapamycin in renal angiomyolipoma associated with tuberous sclerosis complex

Antitumoral activity of rapamycin in renal angiomyolipoma associated with tuberous sclerosis complex

http://www.wikidata.org/entity/Q28259913

about

Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy Aberrant hyperactivation of akt and Mammalian target of rapamycin complex 1 signaling in sporadic chordomas Targeting the mTOR signaling network for cancer therapy Rapamycin and rapalogs for tuberous sclerosis complex Rapamycin and its analogues (rapalogs) for Tuberous Sclerosis Complex-associated tumors: a systematic review on non-randomized studies using meta-analysis Hereditary genodermatoses with cancer predisposition Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex.Topical rapamycin inhibits tuberous sclerosis tumor growth in a nude mouse model.Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis Observations on enhanced port wine stain blanching induced by combined pulsed dye laser and rapamycin administration.Topical rapamycin suppresses the angiogenesis pathways induced by pulsed dye laser: molecular mechanisms of inhibition of regeneration and revascularization of photocoagulated cutaneous blood vessels.Human TSC2-null fibroblast-like cells induce hair follicle neogenesis and hamartoma morphogenesis.t(6;11) renal cell carcinoma (RCC): expanded immunohistochemical profile emphasizing novel RCC markers and report of 10 new genetically confirmed cases Autophagy in the fight against tuberculosis.Key autophagic targets and relevant small-molecule compounds in cancer therapy.Assessing the effectiveness of rapamycin on angiomyolipoma in tuberous sclerosis: a two years trial.Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma.Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors.The long and winding road to rational treatment of cancer associated with LKB1/AMPK/TSC/mTORC1 signaling.Everolimus: an mTOR inhibitor for the treatment of tuberous sclerosis.Research and innovation in the development of everolimus for oncology.Radiofrequency ablation of large renal angiomyolipoma: median-term follow-up.Subependymal giant cell astrocytomas in patients with tuberous sclerosis complex: considerations for surgical or pharmacotherapeutic intervention.UNC51-like kinase 1, autophagic regulator and cancer therapeutic target.Systemic effects of treatment with mTOR inhibitors in tuberous sclerosis complex: a comprehensive review.Pharmacological inhibition of Polo-like kinase 1 (PLK1) by BI-2536 decreases the viability and survival of hamartin and tuberin deficient cells via induction of apoptosis and attenuation of autophagy.A vascular model of Tsc1 deficiency accelerates renal tumor formation with accompanying hemangiosarcomas.Management of epilepsy in tuberous sclerosis complex.Epigalloccatechin-3-gallate inhibits ocular neovascularization and vascular permeability in human retinal pigment epithelial and human retinal microvascular endothelial cells via suppression of MMP-9 and VEGF activation.Clinical management of tuberous sclerosis complex over the lifetime of a patient.Management of the "Other" retroperitoneal sarcomas.Everolimus-induced near-resolution of giant cardiac rhabdomyomas and large renal angiomyolipoma in a newborn with tuberous sclerosis complex.Neurofibromatosis type 1

P2860

Q24628724-CBA6EEF4-4D0D-4312-8ED3-D08049F0BC73 Q24658269-FA065F83-446E-4497-833C-2DCF35D1F68C Q24658334-855659A3-DCF8-4006-B281-4FA5F9B5D194 Q26471128-3D184F04-1628-4FA2-B50E-0CFCD21B2346 Q26799757-6BD65F71-A6C7-4EB9-B96A-00337D96124B Q30470596-5481E161-4096-48E7-AE7C-53E27FC7277D Q30573030-B3081BCE-1AFE-4F4B-BB2A-7EECC9F9F120 Q33316872-42050C65-79C1-435A-B101-C30E7388706E Q34009330-0526E4FE-3182-4D78-8C8B-FACF7B788694 Q34086311-17525763-71D7-44C6-BBBB-C67D504FF35D Q34501488-D9CAD5C9-7221-4CBA-81C2-699D74B3AE9D Q35024472-24C13884-7074-42E9-BE02-1351FB6E3C12 Q35207508-47EDE3F6-5610-4FBF-A642-85ED413ADD40 Q35322096-33DB78F8-1C2E-43F2-8D1B-8F0668E24383 Q35489073-8B45657C-A58F-4928-A6E2-D78A1E2A5C28 Q36459311-12ABA0D4-64BF-4147-A8F2-348767959B67 Q36659706-7ABDDB9D-F960-445A-9913-BA6CCB7D5CB6 Q36735206-9F89B177-330E-4135-A937-84499FDE326A Q37831801-52E92E4A-76D8-4FC8-88C1-3C6D1E85AA19 Q37931887-0D3DB9F9-47FA-4737-98F8-2582C993BA90 Q38014589-91EE82E4-3542-47CA-BDDC-33C969B3649F Q38077133-B364F513-3180-4680-B77B-AA6E03B68052 Q38150748-A6E949C0-2197-4F6D-97E4-50E62120CF12 Q38261262-0B924F8E-7285-4021-856C-032EAFDFAFAF Q38592323-A28616B3-5C36-41D1-BE9E-E38BDA761A7A Q41614453-DF8CC03A-CA95-4F5E-BC56-2FAD27C0F3B1 Q41893057-F5E1F489-45A4-41D8-B934-8DCD5589689A Q46697537-4E319CE7-8659-4E50-BBD5-21EBC1CFD08D Q46852214-C17CA6C0-EED5-4A8E-8CDD-0D1BBB9EB703 Q47826008-1829846D-DB18-4614-98B6-CB4AEEDC212B Q48321145-47DBD6B7-25AF-48D9-A0F8-066DDAF3F3E3 Q53154816-413E35D9-E697-4D88-8E96-C01E73EACC51 Q56093335-284531EC-A0B9-41A6-94C2-4054CBC26407

P2860

Antitumoral activity of rapamycin in renal angiomyolipoma associated with tuberous sclerosis complex

http://www.wikidata.org/entity/Q28259913

description

2006 nî lūn-bûn

@nan

2006 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Antitumoral activity of rapamy ...... ith tuberous sclerosis complex

@ast

Antitumoral activity of rapamy ...... ith tuberous sclerosis complex

@en

Antitumoral activity of rapamy ...... ith tuberous sclerosis complex

@nl

type

label

Antitumoral activity of rapamy ...... ith tuberous sclerosis complex

@ast

Antitumoral activity of rapamy ...... ith tuberous sclerosis complex

@en

Antitumoral activity of rapamy ...... ith tuberous sclerosis complex

@nl

prefLabel

Antitumoral activity of rapamy ...... ith tuberous sclerosis complex

@ast

Antitumoral activity of rapamy ...... ith tuberous sclerosis complex

@en

Antitumoral activity of rapamy ...... ith tuberous sclerosis complex

@nl

P1433

Q28259913-ABCDBB22-D2C5-41CA-A96E-EBCC4653314A

P1476

Q28259913-12274DEE-261C-4F21-B5A7-CF750F8BA1C5

P2093

Q28259913-1EADB44F-BAFE-4F27-BBBD-E8179F429EDE

Q28259913-5F9C3D15-3B17-4F52-B5B4-DFFC11430696

Q28259913-9B015A8D-5924-4DB5-B700-C1745FE5474C

Q28259913-E5ECE91F-5034-408C-B521-0BB9CB8C2DE9

Q28259913-F8293F42-0F2A-459A-A81D-4F33F8488B6A

P304

Q28259913-562D5C80-48BE-4FCE-91C0-3B177CB851C9

P31

Q28259913-8638E74C-0C64-4284-8656-417EBE249E52

P356

Q28259913-25E847FC-0BEF-44B8-AAB7-FDDD782247EC

P407

Q28259913-B7E5201C-B119-44BA-9A4D-D242E99E25A2

P433

Q28259913-6934F7E2-774B-4462-BC8B-27C1664E9CC8

P478

Q28259913-93657C4B-4812-4442-8571-9B397AB99880

P50

Q28259913-D9AFD1C3-E3F7-49AC-A5A4-EC07EA282E92

P577

Q28259913-09A00DC8-C7BA-43D7-92B5-906892D58E4C

P698

Q28259913-31FC2800-5CFB-4BA3-88FE-0E0A61C190AD

P356

J.AJKD.2006.05.018

P1433

American Journal of Kidney Diseases

P1476

Antitumoral activity of rapamy ...... ith tuberous sclerosis complex

@en

P2093

Ingrid Fackler

http://www.w3.org/2001/XMLSchema#string

Karin Mayer

http://www.w3.org/2001/XMLSchema#string

Ralf Wienecke

http://www.w3.org/2001/XMLSchema#string

Thomas Licht

http://www.w3.org/2001/XMLSchema#string

Ulrich Linsenmaier

http://www.w3.org/2001/XMLSchema#string

P304

e27-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1053/J.AJKD.2006.05.018

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

48

http://www.w3.org/2001/XMLSchema#string

P50

Matthias Kretzler

P577

2006-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16931204

http://www.w3.org/2001/XMLSchema#string